🧩 Is tarlatamab the missing piece in frontline ES-SCLC? 📊 Trial: DeLLphi-303 (Phase 1b, n=88, multicenter) 🧬 Regimen: Tarlatamab (DLL3×CD3 bispecific) ➕ PD-L1 inhibitor (Atezolizumab / Durvalumab) ⚡ Setting: First-line maintenance after platinum–etoposide + PD-L1 👥

Protocol of IIT for T-DXd+1st-line chemo+nivolumab for HER2 low gastric/GEJ cancer is published at ESMO Gastrointestinal Oncology ESMO - Eur. Oncology The enrollment is already completed, and the results will be reported in the near future OncoAlert OncoDaily sciencedirect.com/science/articl…

Tar200 now U.S. FDA approved based off #SunRise1: Ph2b, in BCG unresponsive NMIBC. - CR in cohort 2 (TAR200 mono): 82.4% and grade ≥3 AE 12.9% - In papillary DFS at 9mos 81.1% & 70.2% at 12mos - AEs: lower tract UTI symptoms #OncTwitter #MedTwitter #gusm #BladderCancer

More exciting work in the Kras targeting arsenal from Anirban Maitra Kalluri Lab and more

Back to heme/VTE! Some upfront workup for hypercoagulable state. PNH & JAK2 should also be considered for unusual VTE locations. Be mindful of when we ✅ as functional & lupus anticoagulant can be falsely abnormal! #Hematology #HemeTwitter #OncTwitter #MedTwitter #MedX

Revolution Medicines Daraxonrasib data in first line metastatic #PancreaticCancer - monotherapy & combination with Gemcitabine nab-paclitaxel. Even monotherapy ORRs and DCRs are impressive! Do you need the chemo? Grade 3 AEs go from 35% to 58%. RASOLUTE 303 will answer.

It’s out!!! 🔥🔥🔥 The PREOPANC-2 is in The Lancet Oncology Neoadjuvant FOLFIRINOX 🤜🤛 Gemcitabine based chemoradiotherapy in resecatble / BR ⚖️ No difference in overall survival 😰 Serious adverse events 40% 👍 Both regimens may be considered thelancet.com/journals/lanon…

Two important randomized trials in #PancreaticCancer published: 1st PASS-01 in metastatic cancer comparing FOLFIRINOX to Gem/Abraxane (Journal of Clinical Oncology) 2nd PREOPANC-2 in resectable/borderline resectable cancer comparing neoadjuvant FFX versus Gem/CRT (The Lancet Oncology) OncoAlert ⬇️

❓Is esophagectomy always necessary in LA esophageal/GEJ cancer? ⚠️ Surgery = high morbidity/mortality, impaired QoL 📊 SANO: surveillance after cCR noninferior OS 🧪 IO & biomarkers may expand NOM 🚨 Ongoing trials (NEEDS/ESORES/SANO-2) could redefine standards 🔗

Vitamin B12 for prophylaxis of capecitabine-associated hand–foot syndrome 💥Oral methylcobalamin reduced capecitabine-related HFS in HER2-negative early BC, with no added safety concerns 💬A simple prophylaxis option to support treatment adherence bmj.com/content/390/bm…

This is the algorithm for reference during our discussion with Mazyar Shadman, MD MPH on CLL! #HemeTwitter #OncTwitter #MedTwitter OncUpdates #lymsm

New proposed algorithm by a colleague for HER2+ MBC. How the field has evolved. #bcsm

🟤Tislelizumab + ociperlimab +GemCis in 1L treatment of advanced biliary cancers ZSAB-TOP ➡️PD-1/PD-L1 and TIGIT ➡️41 pts, phase 2 , 75% iCCA ✅ORR: 51.2% ✅mPFS: 7.7 mo ✅mOS: 17.4 mo 😮 ❗️AE ≥G3: 60% ➡️Looks promising, phase III RCT is needed 👉nature.com/articles/s4139…

Current USPSTF guidelines for cancer screening. American Cancer Society guidelines for breast ca annual screening starting age 40 can be an “option”. ACS also endorses colonoscopy at 45y/o for colon ca! For ⬆️ risk breast ca & CRC, consider earlier screening! #OncTwitter #MedTwitter

Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer nejm.org/doi/full/10.10…

Adjuvant therapy in colon cancer has come a long way. FOLFOX and capecitabine remain the backbone, but a series of trials highlight how we can go beyond “chemo as usual” to improve both tolerability and efficacy: 🧬 ALASCCA – In stage II–III CRC with PI3K pathway mutations,

Do anthracyclines still matter in high RS HR+/HER2-? 📝 TAILORx post-hoc | N0 HR+/HER2- | RS ≥ 31 💊 Arms: 🔹 TC = Docetaxel + Cyclophosphamide 🔹 T-AC = Taxane + Anthracycline 📊 5-yr outcomes (T-AC vs TC): • 🌍 DRFI: 96.1% vs 91.0% (HR 0.31, p=0.006) • 🧬 DRFS: 95.5% vs

🔥🚨OncoAlert Hot off the press U.S. FDA just approved: ⭐️#Subcutaneous #Pembrolizumab ✅For ALL #Adult & #Pediatric #SolidTumor indications approved for #IV formulation. Approval is based on results of #MK3475A-D77 trial of: #Subcutaneous Vs #IV #Pembrolizumab (+ #Chemo) in

Current National Comprehensive Cancer Network (NCCN) guidelines for germline testing. This is one place where we collectively need to do better not only to ensure we have the discussion for Rx options but this has profound impact on pts family! #OncTwitter #MedTwitter #MedEd #bcsm #lcsm #gusm #gism

The immune microenvironment of colorectal cancer Excellent review👇 nature.com/articles/s4156…